authors
- Curran, Catherine
- Pond, Gregory
- Nassar, Amin
- Abou Alaiwi, Sarah
- McGregor, Bradley Alexander
- Kilbridge, Kerry L
- Sonpavde, Guru
Any regression of tumor (ART) within 12 weeks versus RECIST 1.1 response category as an intermediate endpoint to assess the activity of immune checkpoint inhibitors (ICIs) for metastatic urothelial carcinoma (mUC)
Conferences
- Overview
- Research
- Additional Document Info
- View All
Overview
status
publication date
- February 20, 2020
has subject area
- 1103 Clinical Sciences (FoR)
- 1112 Oncology and Carcinogenesis (FoR)
- Oncology & Carcinogenesis (Science Metrix)
published in
- Journal of Clinical Oncology Journal